Investigating how Parkin helps suppress tumors
Official title: Parkin tumor suppression
Funded at Wistar Institute · NIH-10778455 · Data updated 2026-11-12
This study is looking at how a protein called Parkin, which is connected to early-onset Parkinson's Disease, might help stop cancer from growing by keeping cancer cells in check and boosting the immune system's ability to fight tumors, with the hope of finding new ways to tackle different types of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | August 5, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $499,626 |
| NIH project number | 1R01CA286080-01 |
| Project ID | NIH-10778455 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with various types of cancer, particularly those with early-onset Parkinson's Disease.
✕Less likely to help
Patients with advanced-stage cancers or those without any link to Parkinson's Disease may not benefit from this research.
What this research studies
This research explores the role of Parkin, a protein linked to early-onset Parkinson's Disease, in preventing tumor growth. It focuses on how Parkin inhibits cancer cell movement and metabolism while also enhancing the immune response against tumors. By understanding how Parkin influences immune cells, particularly CD8+ T cells, the research aims to uncover new mechanisms of tumor suppression that could be applicable to various cancers. The study employs a multidisciplinary approach to investigate these processes at the cellular and molecular levels.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the body's immune response to cancer.
How similar studies have gone: Previous research has shown promising results in understanding the immune system's role in tumor suppression, making this approach both innovative and grounded in existing findings.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Altieri, Dario C — Wistar Institute
- Study coordinator: Altieri, Dario C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.